"Predictive Models of the Morphological Evolution of the Human Body to Improve Adherence and Motivation in Dietetic-nutritional Treatments of Overweight and Obesity" [Modelos Predictivos de Evolución Corporal Para Mejorar la Adherencia en Tratamientos de Sobrepeso y Obesidad]
- Conditions
- Body ImageExecutive Function (Cognition)Obesity &Amp;Amp;Amp; Overweight
- Registration Number
- NCT07205029
- Lead Sponsor
- Jorge Azorin Lopez
- Brief Summary
The objective of this clinical trial is to evaluate the effect of a personalized intervention based on the benefits of 4D body modeling and virtual reality techniques, combined with a dietary-nutritional treatment focused on the Mediterranean Diet, as a tool to improve motivation for change, adherence to treatment and health parameters in patients with overweight and obesity. The main research questions to be addressed are:
* How can a 4D computer vision model combined with virtual reality improve clinical diagnoses, the analysis of morphological changes in the human body over time, and adherence to dietary-nutritional treatment?
* Does adherence to an intensive multifactorial dietary-nutritional treatment based on the Mediterranean Diet (MD), supported by 4D immersive virtual reality technology, lead to improvements in cognitive functioning?
* What impact does a nutritional intervention program based on the Mediterranean Diet and the use of virtual reality have on body image perception?
* Can an intensive intervention based on the Mediterranean Diet and 4D virtual reality technology improve overall health? Researchers will compare the control group (which will receive nutritional recommendations based on the Mediterranean Diet) with the experimental group (which will receive nutritional recommendations based on the Mediterranean Diet and visualize their morphological changes through VR) to determine whether a personalized intervention based on the benefits of 4D modeling and virtual reality, combined with a Mediterranean Diet-focused treatment, is effective in addressing overweight and obesity.
Participants are expected to:
* Follow the dietary-nutritional recommendations throughout the 6-month intervention.
* Visit the clinic once a month for follow-up.
* Complete all clinical and psychological assessments.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 133
- a BMI greater than 24.9 kg/m2 [overweight (25 ≥ BMI < 30) and obese (BMI ≥ 30)] according to the BMI classification of the WHO;
- the ability to read and write fluently;
- Spanish as a mother tongue.
- currently being or having been in dietetic-nutritional treatment supervised by a nutritionist in the last year;
- the presence of an endocrine-metabolic disorder (including thyroid, pituitary gland, and adrenal gland problems and metabolic syndrome);
- the presence of a previous history of neurological disease (e.g., stroke or Parkinson's disease) or a history of head trauma;
- the presence of a history of severe psychopathology according to the diagnostic criteria of the DSM-IV-TR;
- currently receiving psychiatric treatment.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Fat in Right Leg From enrollment to the end of treatment at 6 months Fat percentage in the right leg measured using the TANITA MC-780MA P digital scale. Unit of Measure: percent (%).
Fat in Left Leg From enrollment to the end of treatment at 6 months Fat percentage in the left leg measured using the TANITA MC-780MA P digital scale. Unit of Measure: percent (%).
Waist Circumference From enrollment to the end of treatment at 6 months Waist measured with a flexible measuring tape with 0.1 cm precision. Measurements performed twice. Unit of Measure: centimeters (cm).
Hip Circumference From enrollment to the end of treatment at 6 months Hip measured with a flexible measuring tape with 0.1 cm precision. Measurements performed twice. Unit of Measure: centimeters (cm).
Waist-Hip Ratio (WHR) From enrollment to the end of treatment at 6 months Calculated as the ratio of waist to hip circumference. Unit of Measure: ratio (unitless).
Wrist Circumference From enrollment to the end of treatment at 6 months Measured using a flexible measuring tape with 0.1 cm precision. Measurements performed twice. Unit of Measure: centimeters (cm).
Muscle Mass From enrollment to the end of treatment at 6 months Total body muscle mass measured using the TANITA MC-780MA P digital scale. Unit of Measure: kilograms (kg).
Total Body Water From enrollment to the end of treatment at 6 months Total body water percentage measured using the TANITA MC-780MA P digital scale. Unit of Measure: percent (%).
Total Cholesterol From enrollment to the end of treatment at 6 months. Capillary total cholesterol measured using the Accutrend® Plus device (Roche Diagnostics GmbH, Mannheim, Germany) from 15-40 μL blood collected via finger prick (Accu-Chek® Softclix® Pro lancing device). Unit of Measure: mg/dL
Triglycerides From enrollment to the end of treatment at 6 months. Capillary triglycerides measured using the Accutrend® Plus device (Roche Diagnostics GmbH, Mannheim, Germany) from 15-40 μL blood collected via finger prick (Accu-Chek® Softclix® Pro lancing device). Unit of Measure: mg/dL
Systolic Blood Pressure From enrollment to the end of treatment at 6 months. Measured using the M7 Intelli IT sphygmomanometer (OMRON, M7, Corp., Kyoto, Japan). Unit of Measure: mmHg.
Diastolic Blood Pressure From enrollment to the end of treatment at 6 months. Measured using the M7 Intelli IT sphygmomanometer (OMRON, M7, Corp., Kyoto, Japan). Unit of Measure: mmHg.
Interleukin 6 (IL-6) From enrollment to the end of treatment at 6 months. IL-6 measured from peripheral blood obtained via venipuncture using a bead-based multiplex assay (xMAP) with Luminex 200 flow cytometer. Unit of Measure: pg/mL.
Tumor Necrosis Factor Alpha (TNF-α) From enrollment to the end of treatment at 6 months. TNF-α measured from peripheral blood obtained via venipuncture using a bead-based multiplex assay (xMAP) with Luminex 200 flow cytometer. Unit of Measure: pg/mL.
C-Reactive Protein (CRP) From enrollment to the end of treatment at 6 months. Measured in serum samples via immunonephelometry using a Dade Behring BNII nephelometer. Unit of Measure: mg/L.
Cognition: executive function From enrollment to the end of treatment at 6 months. Executive function assessed using the computerized General Cognitive Assessment Battery (CAB) from CogniFit. The battery includes neuropsychological tests evaluating cognitive flexibility, divided attention, planning, visual and auditory perception, spatial perception, contextual memory, short-term visual and auditory memory, non-verbal memory, working memory, processing speed, naming, estimation, monitoring, response time, visual scanning, recognition, hand-eye coordination, focused attention, and inhibition. Test duration ranges from 25 to 45 minutes. Scores range from 0 to 800, with higher scores indicating better cognitive performance. Unit of Measure: CAB score (0-800).
Body Image perception From enrollment to the end of treatment at 6 months. Body image perception assessed using the Spanish short version of the Multidimensional Body-Self Relations Questionnaire (MBSRQ). The questionnaire contains 45 items divided into two parts: General body image perception: scored on a Likert scale from 1 (Totally disagree) to 5 (Totally agree); and Satisfaction with specific body areas: scored on a Likert scale from 1 (Very dissatisfied) to 5 (Very satisfied). Higher scores indicate a more positive body image perception. Unit of Measure: points (Minimum Value: 45 - Maximum Value: 225).
3D and 4D Imaging From enrollment to the end of treatment at 6 months. Morphological 4D images of participants were captured during each session using a 3D imaging system equipped with RGB-D devices. The 4D model represents morphological changes over time. Using cost-effective, wide-spectrum 3D acquisition technologies (RGB-D sensors), a 4D model was constructed as the core of a system for visualizing the human body over time. This model allows for precise and realistic visualization of body changes. Throughout the intervention, 3D morphological images of the participants were obtained, allowing them to observe their physical evolution through immersive Virtual Reality (VR)-a feature available only to the experimental group.
Body Mass Index (BMI) From enrollment to the end of treatment at 6 months BMI was calculated as weight (kg) divided by height squared (m²). According to the WHO classification, overweight will be defined as a BMI ≥ 25.0 kg/m² and obesity as a BMI ≥ 30.0 kg/m².
Body fat From enrollment to the end of treatment at 6 months Body fat percentage measured using a TANITA MC-780MA P digital scale (TANITA Corporation, Arlington Heights, IL, USA). Unit of Measure: percent (%)
Trunk fat From enrollment to the end of treatment at 6 months Fat percentage in the trunk region measured using the TANITA MC-780MA P digital scale. Unit of Measure: percent (%).
Glucose Level From enrollment to the end of treatment at 6 months. Capillary glucose measured using the Accutrend® Plus device (Roche Diagnostics GmbH, Mannheim, Germany) from 15-40 μL blood collected via finger prick (Accu-Chek® Softclix® Pro lancing device). Unit of Measure: mg/dL
Weight From enrollment to the end of treatment at 6 months. Body weight (kg) measured using a calibrated digital scale, a TANITA MC-780MA P digital scale (TANITA Corporation, Arlington Heights, IL, USA). Unit of Measure: kilograms (kg).
Height From enrollment to the end of treatment at 6 months Height measured in standing position without shoes using a SECA 213 portable stadiometer (SECA, Hamburg, Germany). Unit of Measure: meters (m)
Visceral fat From enrollment to the end of treatment at 6 months Visceral fat percentage measured using the TANITA MC-780MA P digital scale. Unit of Measure: percent (%).
Fat in Right Arm From enrollment to the end of treatment at 6 months Fat percentage in the right arm measured using the TANITA MC-780MA P digital scale. Unit of Measure: percent (%).
Fat in Left Arm From enrollment to the end of treatment at 6 months Fat percentage in the left arm measured using the TANITA MC-780MA P digital scale. Unit of Measure: percent (%).
- Secondary Outcome Measures
Name Time Method Nutritional and Lifestyle measures: Physical Activity From enrollment to the end of treatment at 6 months. Physical activity over the previous 7 days assessed using the International Physical Activity Questionnaire (IPAQ), Spanish Version, including 7 questions on frequency, duration, and intensity (vigorous and moderate), walking, and time spent sitting on a typical weekday. Higher scores indicate higher levels of physical activity. Unit of Measure: MET-minutes/week.
Nutritional and Lifestyle measures: Adherence to the Mediterranean Diet From enrollment to the end of treatment at 6 months. Assessed using the 14-item PREDIMED Mediterranean Diet Adherence Questionnaire. Each item scores 0 or 1. Total scores range from 0 to 14, with scores ≥ 8 indicating good adherence and \< 8 indicating low adherence to the Mediterranean Diet. Higher scores indicate better adherence. Unit of Measure: points (Minimum Value: 0 - Maximum Value: 14).
Nutritional and Lifestyle measures: Food Frequency Questionnaire From enrollment to the end of treatment at 6 months. Dietary habits assessed using a 118-item Food Frequency Questionnaire adapted for the Spanish population. Scores range from 0 (never or \<1/month) to 8 (+6 times per day). Higher scores indicate higher frequency of consumption of the specified food items. Unit of Measure: frequency (Minimum Value: 0 - Maximum Value: 8).
Nutritional and Lifestyle measures: 24-Hour Dietary Recall From enrollment to the end of treatment at 6 months. Dietary intake assessed via three 24-hour dietary recalls (two weekdays and one weekend/holiday) to estimate nutrient and caloric intake. Higher values indicate higher intake. Unit of Measure: kilocalories (kcal) and grams of macronutrients per day.
Psychological measures: Premorbid Intelligence From enrollment to the end of treatment at 6 months. Premorbid intelligence estimated based on the correct accentuation of 30 words, assessed using the Word Accentuation Test (TAP). The number of correct responses corresponds to an estimated IQ score based on the WAIS-IV scale. Higher scores indicate higher estimated premorbid intelligence. Unit of Measure: IQ points.
Psychological Measures: Emotional Eating From enrollment to the end of treatment at 6 months. Assesses the influence of emotions on food choices through the Emotional Eater Questionnaire (CCE). 10 items scored on a Likert scale from 0 (Never) to 3 (Always). Higher scores indicate greater emotional influence on eating habits. Unit of Measure: points (Minimum Value: 0 - Maximum Value: 30).
Psychological Measures: Prefrontal Symptoms From enrollment to the end of treatment at 6 months. Self-reported measure of cognitive, emotional, and behavioral disturbances in daily life, assessed using the Prefrontal Symptom Inventory, ISP-20 (Abbreviated Version). 20 items scored on a Likert scale from 0 (Never/almost never) to 4 (Always/almost always). Higher scores indicate more severe prefrontal symptoms. Unit of Measure: points (Minimum Value: 0 - Maximum Value: 80).
Psychological Measures: Impulsivity From enrollment to the end of treatment at 6 months. Measures impulsivity across three subscales: cognitive (8 items), motor (10 items), and non-planning (12 items), assessed using the Barratt Impulsiveness Scale, BIS-11. Each item scored 0-4 (0=Rarely/Never, 4=Almost Always). Higher scores indicate greater impulsivity. Unit of Measure: points (Minimum Value: 0 - Maximum Value: 120).
Psychological Measures: Health-Related Quality of Life From enrollment to the end of treatment at 6 months. Assesses physical and mental health-related quality of life using the Short Form-12 Health Survey (SF-12). 12 items scored from 0 (worst health) to 100 (best health). Higher scores indicate better health-related quality of life. Unit of Measure: points (Minimum Value: 0 - Maximum Value: 100).
Psychological Measures: Depression From enrollment to the end of treatment at 6 months. 21-item self-report questionnaire assessing depressive symptoms, measured using the Beck Depression Inventory-II (BDI-II). Items scored 0 (Not at all) to 3 (Severely). Higher scores indicate more severe depressive symptoms. Unit of Measure: points (Minimum Value: 0 - Maximum Value: 63).
Psychological Measures: Life Satisfaction From enrollment to the end of treatment at 6 months. Measures global life satisfaction using the Satisfaction With Life Scale (SWLS). 5 items scored on a 7-point Likert scale (1=Completely disagree, 7=Completely agree). Higher scores indicate greater life satisfaction. Unit of Measure: points (Minimum Value: 5 - Maximum Value: 35).
Trial Locations
- Locations (1)
University of Alicante
🇪🇸Alicante, Alicante, Spain
University of Alicante🇪🇸Alicante, Alicante, Spain